Literature DB >> 1233077

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.

V K Lui, J Karpuchas, P B Dent, P B McCulloch, M A Blajchman.   

Abstract

Cell mediated immunocompetence was measured serially in 35 patients with malignant melanoma in order to determine the effect of extent of disease and prognosis as well as the influence of BCG immunotherapy on immune reactivity. Compared with normal adult controls, statistically significant lymphopenia occurred only in patients with widespread disease. Seventeen of 21 patients with negative pre-therapy PPD skin test converted to skin test positivity. PHA blastogenesis was depressed only in patients in the pre-terminal stages of their disease using optimal mitogen concentrations for stimulation. Threshold concentrations of this mitogen more clearly demonstrated a depressed responsiveness which correlated in severity with extent of disease. PPD induced blastogenesis was normal or increased in the majority of patients; however, the degree of stimulation by PPD was less in the BCG induced convertors than in those patients who were skin test positive before BCG treatment. Comparison of the pre- and post BCG assessments reveals no significant differences except in relation to PPD conversion. We conclude that using threshold concentrations of PHA, impaired responses are regularly associated with disease beyond the regional lymph nodes. Routine assessment of lymphocyte function by these parameters did not provide information that was not available from clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233077      PMCID: PMC2024745          DOI: 10.1038/bjc.1975.230

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

Review 1.  Impaired immunoresponsiveness in tumor patients.

Authors:  J Harris; D Copeland
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

2.  Effect of BCG on delayed hypersensitivity responses of patients with neoplastic disease.

Authors:  J E Sokal; C W Aungst; T Han
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

3.  Correlation of in vivo and in vitro assays of immunocompetence in cancer patients.

Authors:  S H Golub; T X O'Connell; D L Morton
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

4.  Cell-mediated immunity in acute nonlymphocytic leukemia: relationship to host factors, therapy, and prognosis.

Authors:  W H Greene; S C Schimpff; P H Wiernik
Journal:  Blood       Date:  1974-01       Impact factor: 22.113

5.  Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.

Authors:  L Chess; G N Bock; P C Ungaro; D H Buchholz; M R Mardiney
Journal:  J Natl Cancer Inst       Date:  1973-07       Impact factor: 13.506

6.  Abnormalities in lymphocyte proliferation in classical and atypical measles infection.

Authors:  A Finkel; P B Dent
Journal:  Cell Immunol       Date:  1973-01       Impact factor: 4.868

7.  The delayed hypersensitivity reaction in cancer patient: observations on sensitization by DNCB.

Authors:  R C Chakravorty; H P Curutchet; F S Coppolla; C M Park; W K Blaylock; W Lawrence
Journal:  Surgery       Date:  1973-05       Impact factor: 3.982

8.  The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli.

Authors:  J J Oppenheim; B G Leventhal; E M Hersh
Journal:  J Immunol       Date:  1968-08       Impact factor: 5.422

9.  Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology.

Authors:  W J Catalona; P B Chretien
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

10.  Immunologic studies in patients with malignant melanoma in Uganda.

Authors:  J L Ziegler; M G Lewis; J M Luyombya; J W Kiryabwire
Journal:  Br J Cancer       Date:  1969-12       Impact factor: 7.640

View more
  7 in total

Review 1.  Learning from clinical trials of neoadjuvant checkpoint blockade.

Authors:  Judith M Versluis; Georgina V Long; Christian U Blank
Journal:  Nat Med       Date:  2020-04-09       Impact factor: 53.440

2.  Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

3.  Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.

Authors:  P B McCulloch; P B Dent; M Blajchman; W M Muirhead; R A Price
Journal:  Can Med Assoc J       Date:  1977-07-09       Impact factor: 8.262

4.  Evaluation of the immunocompetance of patients with transitional cell carcinoma of the bladder.

Authors:  H D Adolphs; L Steffens
Journal:  Urol Res       Date:  1977

Review 5.  Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Authors:  Elizabeth Ahern; Ben J Solomon; Rina Hui; Nick Pavlakis; Ken O'Byrne; Brett G M Hughes
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 6.  Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.

Authors:  Virginia Ferraresi; Sabrina Vari
Journal:  Hum Vaccin Immunother       Date:  2021-12-09       Impact factor: 4.526

Review 7.  Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

Authors:  Judith M Versluis; Daniela S Thommen; Christian U Blank
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.